Video

Thomas P. Miller Expects a Flurry of Activity if SCOTUS Rules for Plaintiffs in King v. Burwell

Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.

The predictions of so-called "death spirals" in insurance markets in states on the federal exchange resulting from a Supreme Court decision in King v. Burwell for the plaintiffs may be overblown, according to Thomas P. Miller, JD, resident fellow at the American Enterprise Institute.

Although there will be changes in the marketplace if the Supreme Court decision makes residents in states using HealthCare.gov ineligible for subsidies, it won't be anything that is irreversible. Something will be done in the event of a decision favorable for King, whether it is the Obama administration reversing course or the state reviewing their options for exchanges.

"I think there will be a flurry of activity—after the first round of finger pointing and blame shifting in Congress—to actually being to work on something that neither side will have as their first choice but will end up being the compromise that they have to do because they don't have another alternative," Mr Miller said.

Related Videos
Screenshot from interview with Andrew Evens, DO
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center
Jawad Haider Butt, MD, PhD
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo